Last reviewed · How we verify

Esomeprazole IV

AstraZeneca · Phase 3 active Small molecule

Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.

Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.

At a glance

Generic nameEsomeprazole IV
SponsorAstraZeneca
Drug classProton pump inhibitor (PPI)
TargetH+/K+-ATPase (proton pump)
ModalitySmall molecule
Therapeutic areaGastroenterology
PhasePhase 3

Mechanism of action

Esomeprazole is the active S-enantiomer of omeprazole. It binds to and inactivates the proton pump (H+/K+-ATPase) on the secretory surface of gastric parietal cells, preventing the final step of gastric acid production. This results in profound and sustained reduction of both basal and stimulated gastric acid secretion, providing rapid symptom relief and promoting healing of acid-related lesions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results